Clinical features and pathological findings by liver biopsy in patients with immune-related sclerosing cholangitis induced by immune checkpoint inhibitors
- 18 January 2025
- journal article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (4) , 877-884
Abstract
No abstract availableKeywords
Funding Information
- National Center for Global Health and Medicine (23A1002)
This publication has 26 references indexed in Scilit:
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Pembrolizumab-related cholangitis with multiple fatal liver abscesses after endoscopic biliary drainage: a case report and review of the literatureClinical Journal of Gastroenterology, 2022
- Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignanciesHepatology International, 2021
- IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expressionJournal of Hepatology, 2020
- Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management RecommendationHepatology, 2020
- Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignanciesJournal of Gastroenterology, 2020
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitorsJournal of Hepatology, 2018
- Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case reportCancer Immunology, Immunotherapy, 2017
- Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancerInvestigational New Drugs, 2017
- Management of toxicities of immune checkpoint inhibitorsCancer Treatment Reviews, 2016